BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HNC364 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HNC364\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06798519-1643@assetmemo.bio
DTSTAMP:20261121T005443Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HNC364: Phase 1 readout est. (NCT06798519)
DESCRIPTION:HNC364\, phase 1\, Parkinson's Disease.\nStudy: Relative Bioava
 ilability Study of HNC364 Injectable Suspension\nEstimated primary complet
 ion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/hnc364#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06798519
URL:https://assetmemo.bio/drug/hnc364#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
